financetom
Business
financetom
/
Business
/
Nvidia's Jensen Huang: 'China is going to win the AI race,' FT reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia's Jensen Huang: 'China is going to win the AI race,' FT reports
Nov 5, 2025 4:23 PM

(Reuters) -Nvidia ( NVDA ) CEO Jensen Huang has warned that China will beat the United States in the artificial intelligence race, the Financial Times reported on Wednesday.

"China is going to win the AI race," Huang told the newspaper on the sidelines of the Financial Times' Future of AI Summit.

"As I have long said, China is nanoseconds behind America in AI," Nvidia ( NVDA ) CEO Jensen Huang said in a statement posted on X late on Wednesday.

"It's vital that America wins by racing ahead and winning developers worldwide," he added.

The artificial intelligence chip leader's chief in October said that the U.S. can win the AI battle if the world, including China's massive developer base, runs on Nvidia ( NVDA ) systems. He, however, lamented that the Chinese government has shut it out of its market.

China's access to advanced AI chips, particularly those produced by Nvidia ( NVDA ) - the world's most valuable company by market capitalization - remains a flashpoint in its tech rivalry with the United States, as both nations vie for supremacy in cutting-edge computing and artificial intelligence.

"We want America to win this AI race. No doubt about that," Huang said in the Nvidia ( NVDA ) developers' conference held in Washington last month.

"We want the world to be built on American tech stack. Absolutely the case. But we also need to be in China to win their developers. A policy that causes America to lose half of the world's AI developers is not beneficial in the long term, it hurts us more," he added.

U.S. President Donald Trump said in an interview aired on Sunday that Nvidia's ( NVDA ) most advanced Blackwell chips should be reserved exclusively for American customers.

Nvidia ( NVDA ) has not applied for U.S. export licenses to sell the chips in China, citing Beijing's stance toward the company, CEO Jensen Huang previously said.

Trump added that Washington would allow China to engage with Nvidia ( NVDA ), but "not in terms of the most advanced" semiconductors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Weight-loss drug developer BioAge raises $198 mln in US IPO
Weight-loss drug developer BioAge raises $198 mln in US IPO
Sep 25, 2024
Sept 25 (Reuters) - BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday. ...
Oppenheimer Holdings to Redeem $113 Million of Senior Notes Due 2025
Oppenheimer Holdings to Redeem $113 Million of Senior Notes Due 2025
Sep 25, 2024
10:40 AM EDT, 09/19/2024 (MT Newswires) -- Oppenheimer Holdings ( OPY ) said Thursday it sent a notice to holders of its 5.50% senior secured notes due 2025, indicating its intent to redeem about $113.1 million on Oct. 10. The redemption price will be 100% of the principal amount, plus any accrued and unpaid interest, the company said. Once the...
BRIEF-BioAge Labs Announces Pricing Of Upsized Initial Public Offering Of 11 Million Shares At $18.00 Per Share
BRIEF-BioAge Labs Announces Pricing Of Upsized Initial Public Offering Of 11 Million Shares At $18.00 Per Share
Sep 25, 2024
Sept 25 (Reuters) - * BIOAGE LABS ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING * BIOAGE LABS, INC- ANNOUNCED PRICING OF UPSIZED INITIAL PUBLIC OFFERING OF 11 MILLION SHARES AT A PUBLIC OFFERING PRICE OF $18.00 PER SHARE Source text for Eikon: ...
Axonics defeats Medtronic lawsuit in spine-stimulation patent trial
Axonics defeats Medtronic lawsuit in spine-stimulation patent trial
Sep 25, 2024
Sept 19 (Reuters) - Medical device maker Axonics ( AXNX ) has convinced a jury in California federal court that it did not violate rival Medtronic's ( MDT ) patent rights in nerve-stimulation technology. The jury agreed with Axonics ( AXNX ) on Wednesday that its R15 neurostimulation system did not infringe Medtronic ( MDT ) patents related to its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved